MoonLake Immunotherapeutics
NASDAQ:MLTX · NASDAQ Capital Market
+$0.13 today
Vol 0.77M · Avg 0.99M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $298.5M |
| Short-term Investments | $59.4M |
| Receivables | $5.8M |
| Other Current | $33.0M |
| Total Current Assets | $396.6M |
| PP&E (Net) | $2.4M |
| Other Non-current | $1.3M |
| Total Non-current Assets | $3.7M |
| Total Assets | $400.4M |
Analysis
Selected assets total $400.4M for Latest. The largest visible component is Cash & Equivalents at $298.5M, about 74.6% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $334.5M +85.4% | $180.4M -60.0% | $451.2M +1042.0% | $39.5M +391.4% | $8.0M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $59.5M -77.8% | $267.6M +347.2% | $59.8M +83.5% | $32.6M | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $4.9M +71.3% | $2.8M +169.0% | $1.1M +386.7% | $217.1K +45.9% | $148.8K | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $421.7M -11.1% | $474.3M -7.8% | $514.2M +572.0% | $76.5M +694.0% | $9.6M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $2.1M -41.2% | $3.6M -7.7% | $3.9M +1089.7% | $332.0K +625.8% | $45.7K | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 -100.0% | $115.0M | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $596.0K | $0 -100.0% | $8.4M +315291949351456931840.0% | -$0 +100.0% | -$115.0M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $2.7M -24.8% | $3.6M -70.5% | $12.4M +3627.1% | $332.0K +625.8% | $45.7K | -$15.3B | $14.8B | $11.3B |
| Total Assets | $424.4M -11.2% | $477.9M -9.2% | $526.5M +585.2% | $76.8M +693.6% | $9.7M | $13.3B | $11.9B | $10.6B |
| Account Payables | $0 -100.0% | $8.7M +492.4% | $1.5M +2985.3% | $47.5K -96.1% | $1.2M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $1.2M | $0 | $0 | $0 -100.0% | $15.0M | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $642.1K +74.5% | $368.0K +235.1% | $109.8K +71.8% | $63.9K | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $40.8M +863.6% | $4.2M +52.4% | $2.8M +2431.5% | $109.8K -91.5% | $1.3M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $45.5M +102.4% | $22.5M +125.4% | $10.0M +30.0% | $7.7M -63.6% | $21.1M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $74.5M | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | -$374.0K -160.3% | $620.7K +6.4% | $583.4K +106.7% | $282.2K +17.7% | $239.9K | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $74.5M +3483.4% | $2.1M -32.6% | $3.1M +649.9% | $411.2K +71.4% | $239.9K | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $120.0M +388.8% | $24.5M +88.1% | $13.0M +61.6% | $8.1M -62.1% | $21.3M | $14.7B | $3.7B | $9.6B |
| Common Stock | $7.0K +9.5% | $6.4K +1.5% | $6.3K +19.5% | $5.3K -86.3% | $38.5K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$462.9M -96.5% | -$235.6M -102.0% | -$116.7M -44.6% | -$80.7M -50.3% | -$53.6M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $604.0K -87.9% | $5.0M +111.9% | $2.4M +571.8% | $350.9K +308.7% | -$168.2K | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 -100.0% | $6.6M -63.1% | $17.8M -10.3% | $19.9M | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $304.5M -32.8% | $453.4M -11.7% | $513.5M +646.7% | $68.8M +690.5% | -$11.6M | $9.1B | $7.7B | $3.3B |
| Total Debt | $75.7M +2575.6% | $2.8M -23.5% | $3.7M +1208.6% | $282.6K -98.1% | $15.0M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$258.8M -45.7% | -$177.6M +60.3% | -$447.5M -1040.8% | -$39.2M -663.5% | $7.0M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.32B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.47B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.37B
Absci Corporation
NASDAQ:ABSI
$1.13B
MeiraGTx Holdings plc
NASDAQ:MGTX
$1.02B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$797.05M
CytomX Therapeutics, Inc.
NASDAQ:CTMX
$472.82M
REGENXBIO Inc.
NASDAQ:RGNX
$411.00M
Verastem, Inc.
NASDAQ:VSTM
$291.81M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does MLTX have?
MoonLake Immunotherapeutics (MLTX) reported $334.52M in cash and equivalents in fiscal 2025.
How much debt does MLTX carry?
MoonLake Immunotherapeutics (MLTX) reported $75.71M of total debt, with net debt of -$258,809,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.